Vaccine stands for a preparation of dead, attenuate or else modified viruses, bacteria and other microorganisms utilized as an inoculation to immunize against any disease by way of stimulating antibodies’ production. With constant technology upgrades and launches of new medicinal products, Vaccines proved to be the most sophisticated healthcare aid ever created in the pharma’s history.
The global Vaccine Industry is thriving mainly owing to the chronic availability of different diseases, both already-existing and cropping up on the horizon, which can be luckily prevented with Vaccines’ assistance. Pediatric Vaccines form the largest and the most hastily evolving segment as against adult Vaccines, with the trend predicted to stay unaltered in the impending period. The worldwide Vaccine Market is primarily in the paws of such behemoths as Merck & Company, Inc.; Novartis, Pfizer, Inc.; GlaxoSmithKline plc; and Sanofi Pasteur.
The research reports under this Catalogue provide in-depth assessments of the global Vaccine Industry, discussing pressing market issues and statistical figures. The research reports cover the sizing (value/volume) and short-to-long-run forecasts for the overall Vaccine Market and its major segments, and for numerous geographic markets. The listing of M&As among the Vaccine universe participants with new products’ reviews, alongside company profile information can be derived from the research reports too.
Publications found:
977
Sort by:
Competitor Analysis: CMV Vaccines & Therapeutics
US$ 247.00
... approved for treatment or prevention of CMV disease, such as ganciclovir, or hyperimmune globulin preparations, but no specific CMV vaccine is approved. The present Competitor Analysis describes the R&D pipeline of new molecular entities including vaccines, monoclonal antibodies, peptides, cellular therapy ...
August 2012
23 pages
Competitor Analysis: Dengue Virus Vaccines and Therapeutics
US$ 243.00
... of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...
July 2012
27 pages
Competitor Analysis: RSV Vaccines and Therapeutics
US$ 315.00
Competitor Analysis: Respiratory Syncytial Virus (RSV) Vaccines and Therapeutics The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a ... RSV disease in infants and children at high risk for severe lung disease from RSV, a RSV vaccine still is not on the market. A number ...
June 2012
30 pages
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
US$ 394.00
The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules as well as DNA-, RNA- and microorganism-based therapies against infection with ...
May 2012
46 pages
Research Report on Chinese Human Vaccine Industry, 2012
US$ 3,000.00
The research object of the report is human vaccine apart from animal vaccine. Vaccination is the most economical, effective, safe and convenient way to prevent disease and the investment of vaccinatio...
March 2012
50 pages
Vaccine Pipeline Database: 1-Year Subscription
US$ 1,333.00
Subscription to La Merie’s proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use ...
October 2011
274 pages
Competitor Analysis HIV Vaccines
US$ 413.00
... (plasmid, conventional, alternative delivery and prime – boost regimens) Adenoviral vector vaccines Poxvirus vector vaccines Protein & peptide vaccines Others Corporate HIV Vaccine R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise ...
October 2011
54 pages
Competitor Analysis: Hepatitis Vaccines
US$ 498.00
... Vaccines Combination Vaccines including HAV Vaccines Combination Vaccines including HBV Vaccines Hepatitis C Virus Vaccines Hepatitis E Virus Vaccines Corporate Hepatitis Vaccine Product Portfolios and R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but ...
June 2011
96 pages
Competitor Analysis Influenza Vaccines
US$ 718.00
... of seasonal and pandemic influenza disease. In addition, the report lists company-specific product portfolios and R&D pipelines of influenza vaccines on the market and in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of ...
May 2011
123 pages
China Vaccine Industry Report, 2009-2010
US$ 1,900.00
Price:Hard Copy: US$ 1,900.00 PDF for Single User: US$ 2,000.00 PDF for Enterprisewide: US$ 3,000.00Being one of the world's largest vaccine producers, China not only has many vaccine companies, vari...
September 2010
111 pages
Competitor Analysis: Streptococcal Vaccines and Antibodies
US$ 230.00
... A Streptococcus Group B Streptococcus Other Streptococcal Vaccine & Antibody R&D Agreements Corporate Streptococcal Vaccines & Antibody R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D ...
June 2010
18 pages
Competitor Analysis: P. aeruginosa Vaccines and Therapeutics
US$ 230.00
... P. aeruginosa Peptides P. Aeruginosa Small Molecules P. aeruginosa R&D Licensing Agreements Corporate P. aeruginosa Vaccines & Therapeutics R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of ...
June 2010
22 pages
Competitor Analysis: HPV Vaccines
US$ 172.50
... of the three recommended doses when they were younger. The approved vaccines protect against two or four, respectively, most common types ... a hyperlink leading to the source of information. Index HPV Vaccines Corporate HPV Vaccines R&D Pipelines About La Merie About Competitor Analysis Series The ...
May 2010
18 pages
Research Report Chinese Bird Flu Vaccine Industry, 2009
US$ 1,414.50
Zoonosis refers to a kind of infectious disease that plagues between animals and human beings. Some plagues, though discovered, spread widely all over the world. Others are newly found, such as the sw...
April 2009
60 pages
Research Report on China's Animal Vaccine Industry, 2009
US$ 1,552.50
In 2008, the market size of Chinese animal vaccine is about 3 billion Yuan (0.43 billion US Dollars), increased by 30% in 2007, and will still keep a fast growth in years. This depends on many factors...
March 2009
60 pages
Research Report on China Avian Influenza Vaccine Industry, 2014-2018
US$ 1,800.00
... avian influenza vaccines voluntarily 10 years ago without compulsory requirements. Chinese avian influenza vaccine industry was in the initial stage in 2001-2005 ... Influenza Vaccines and the Operation Status in China Prospect of China Avian Influenza Vaccine Industry The Following Enterprises and People Are ...
September 2026
-
Research Report on China Swine Fever Vaccine Industry, 2014-2018
US$ 1,800.00
... while the stock volume of fattened pigs was 715.57 million, up by 2.5% YOY. Swine fever is considered a highly infectious disease that needs strict prevention, ... Swine Fever Vaccines and the Operation Status in China Prospect of China Swine Fever Vaccine Industry The Following Enterprises and People Are ...
September 2026
-
Global In Ovo Vaccination Equipment Market Growth 2026-2032
US$ 3,660.00
The global In Ovo Vaccination Equipment market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032. United States market f...
September 2026
84 pages
